Hanna Berglund
Uppsala, C 75185, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
[161Tb]Tb-DOTATATE as a potential treatment option for neuroblastoma.
Journal: EJNMMI research
Published: April 13, 2026
Correction: Enhancing glioblastoma therapy: unveiling synergistic anticancer effects of Onalespib - radiotherapy combination therapy.
Journal: Frontiers in oncology
Published: March 05, 2026
Author Correction: Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.
Journal: Scientific reports
Published: July 29, 2025
Preclinical Validation of [177Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: July 03, 2025
Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts.
Journal: Molecular cancer therapeutics
Published: June 29, 2024
Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.
Journal: Scientific reports
Published: July 14, 2023
p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts.
Journal: European journal of nuclear medicine and molecular imaging
Published: June 21, 2023
Dual targeting of G9a and DNMTs induces antitumor effects in multiple myeloma.
Journal: Blood advances
Published: May 09, 2023
p53-Mediated Radiosensitization of 177Lu-DOTATATE in Neuroblastoma Tumor Spheroids.
Journal: Biomolecules
Published: September 29, 2021
Maternal prenatal depressive symptoms and toddler behavior: an umbilical cord blood epigenome-wide association study.
Journal: Translational psychiatry
Published: December 04, 2020
Last Updated: 09/26/2026